Properties (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
company
|
| gptkbp:acquisition |
gptkb:Takeda_Pharmaceutical_Company
2018 $62 billion |
| gptkbp:CEO |
gptkb:Dr._Takeda
|
| gptkbp:employees |
over 23,000
|
| gptkbp:founded |
1986
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire Group
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:partnerships |
collaborations with biotech firms
alliances with academic institutions joint ventures in drug development |
| gptkbp:philanthropy |
community health programs
support for patient advocacy groups donations to healthcare initiatives educational grants for healthcare professionals research funding for rare diseases |
| gptkbp:products |
gptkb:Elaprase
Adderall Cerezyme Fabrazyme Intuniv Replagal Vyvanse Myalept Vpriv Cystic fibrosis treatments Growth hormone deficiency treatments Attention deficit hyperactivity disorder (ADHD) treatments Hemophilia_treatments Gaucher_disease_treatments |
| gptkbp:researchAndDevelopment |
focus on neuroscience
focus on immunology focus on endocrinology focus on genetic diseases focus on hematology focus on ophthalmics |
| gptkbp:revenue |
$15.2 billion (2017)
|
| gptkbp:specializesIn |
rare diseases
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
SHPG
|
| gptkbp:subsidiary |
gptkb:Shire_Pharmaceuticals_LLC
gptkb:Shire_International_GmbH gptkb:Shire_Human_Genetic_Therapies_Inc. gptkb:Shire_Development_LLC |
| gptkbp:website |
www.shire.com
|